The interaction between our capsule-based DPI and proprietary formulation creates an ideal aerodynamic profile that allows for deep lung delivery of our active ingredient. This translates to rapid absorption and therapeutic effect. Asprihale® consists of a capsule-based DPI and two capsules for inhalation that will be administered at the onset of MI symptoms.
Asprihale® is absorbed much faster than the RLD, which is the current standard-of-care. Clinical results established the maximum concentration of the active ingredient in two minutes.